MediciNova Advances Potential Breakthrough Treatment for Brain Metastasis
La Jolla, Tuesday, 28 April 2026.
A recent study reveals MediciNova’s drug ibudilast successfully suppresses brain metastasis growth, marking a significant clinical advancement in treating one of oncology’s most challenging frontiers.
Unlocking the Immune Microenvironment
On April 27, 2026, MediciNova, Inc. announced a critical scientific milestone stemming from research conducted at the Spanish National Cancer Research Centre (CNIO) [1]. The study, published in the peer-reviewed journal “Cancer Research” in March 2026, pinpointed a central vulnerability in the development of brain metastases [1][2]. Led by Dr. Manuel Valiente, the research team discovered that a tumor-derived protein known as macrophage migration inhibitory factor (MIF) fundamentally alters microglia and macrophages within the brain [1]. This alteration essentially hijacks these immune cells, reprogramming them to adopt a pro-metastatic role that facilitates tumor growth [1]. By identifying the MIF-mediated reprogramming of CD74-positive cells, researchers have uncovered a highly actionable target within the brain’s immune microenvironment [1][2].
Ibudilast’s Role in Halting Metastasis
The breakthrough centers on the pharmacological modulation of this newly identified pathway using MediciNova’s brain-penetrant small molecule, ibudilast (also known as MN-166) [2]. According to the CNIO study, inhibiting the MIF–CD74 signaling axis with ibudilast successfully reversed the pro-metastatic immune reprogramming [1]. In both experimental preclinical models and patient-derived brain metastasis samples, the administration of the drug effectively blocked the signaling pathway and significantly suppressed the growth and progression of brain metastases [1][2]. This demonstrates the compound’s ability to cross the blood-brain barrier and directly alter the tumor microenvironment [2].
Strategic Clinical Translation and Future Prospects
Capitalizing on these promising preclinical results, MediciNova is now pivoting toward clinical translation. The company announced plans to collaborate directly with Dr. Valiente and the CNIO to design and initiate future clinical research specifically targeting patients who have solid tumors with brain metastases [1]. Dr. Kazuko Matsuda, Chief Medical Officer at MediciNova, emphasized that brain metastasis is one of oncology’s most urgent frontiers [1]. She also highlighted a critical commercial advantage for the firm: MediciNova currently holds granted patents covering the use of MN-166 for the prevention and minimization of cancer metastasis across multiple solid tumor types [1].